S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

SeaSpine Stock Forecast, Price & News

+0.01 (+0.08%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
108,947 shs
Average Volume
101,939 shs
Market Capitalization
$435.48 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SPNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SeaSpine and its competitors with MarketBeat's FREE daily newsletter.

SeaSpine logo

About SeaSpine

SeaSpine Holdings Corp. operates as a medical technology company. The firm engages in the design, developmen and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. It products include thoracolumbar hardware, cervical hardware, orthobiologics, and spine pure strip. The company was founded on February 12, 2015 and is headquartered in Carlsbad, CA.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$154.35 million
Book Value
$6.21 per share


Net Income
$-43.18 million
Pretax Margin




Free Float
Market Cap
$435.48 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.26 out of 5 stars

Medical Sector

332nd out of 1,418 stocks

Surgical & Medical Instruments Industry

38th out of 130 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

SeaSpine (NASDAQ:SPNE) Frequently Asked Questions

Is SeaSpine a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SeaSpine stock.
View analyst ratings for SeaSpine
or view top-rated stocks.

How has SeaSpine's stock been impacted by Coronavirus?

SeaSpine's stock was trading at $10.73 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SPNE shares have increased by 11.4% and is now trading at $11.95.
View which stocks have been most impacted by COVID-19

When is SeaSpine's next earnings date?

SeaSpine is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for SeaSpine

How were SeaSpine's earnings last quarter?

SeaSpine Holdings Co. (NASDAQ:SPNE) announced its quarterly earnings results on Thursday, October, 28th. The medical equipment provider reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.17. The medical equipment provider earned $46.45 million during the quarter, compared to the consensus estimate of $45.66 million. SeaSpine had a negative net margin of 25.18% and a negative trailing twelve-month return on equity of 20.88%. The company's revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the company earned ($0.24) earnings per share.
View SeaSpine's earnings history

What guidance has SeaSpine issued on next quarter's earnings?

SeaSpine issued an update on its fourth quarter 2021 earnings guidance on Thursday, November, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $54 million-$55 million, compared to the consensus revenue estimate of $58.61 million.

What price target have analysts set for SPNE?

5 Wall Street analysts have issued 1-year price objectives for SeaSpine's shares. Their forecasts range from $20.00 to $100.00. On average, they anticipate SeaSpine's stock price to reach $37.80 in the next twelve months. This suggests a possible upside of 216.3% from the stock's current price.
View analysts' price targets for SeaSpine
or view top-rated stocks among Wall Street analysts.

Who are SeaSpine's key executives?

SeaSpine's management team includes the following people:
  • Keith C. Valentine, President, Chief Executive Officer & Director
  • John J. Bostjancic, Chief Financial Officer, Treasurer & Senior VP
  • Chris Shen, VP-Information Technology & Customer Experience
  • Frank Vizesi, Vice President-Clinical Affairs
  • Patrick L. Keran, Secretary, Senior Vice President & General Counsel

What is Keith Valentine's approval rating as SeaSpine's CEO?

23 employees have rated SeaSpine CEO Keith Valentine on Glassdoor.com. Keith Valentine has an approval rating of 79% among SeaSpine's employees.

What other stocks do shareholders of SeaSpine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SeaSpine investors own include AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Kura Oncology (KURA), Recro Pharma (REPH), Rigel Pharmaceuticals (RIGL), Spectrum Pharmaceuticals (SPPI), ViewRay (VRAY), Verastem (VSTM) and Akorn (AKRX).

What is SeaSpine's stock symbol?

SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."

Who are SeaSpine's major shareholders?

SeaSpine's stock is owned by a number of institutional and retail investors. Top institutional investors include HighMark Wealth Management LLC (0.82%). Company insiders that own SeaSpine stock include Beau Standish, John B Henneman III, Renee Gaeta and Richard E Caruso.
View institutional ownership trends for SeaSpine

Which institutional investors are buying SeaSpine stock?

SPNE stock was acquired by a variety of institutional investors in the last quarter, including HighMark Wealth Management LLC.
View insider buying and selling activity for SeaSpine
or or view top insider-buying stocks.

How do I buy shares of SeaSpine?

Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SeaSpine's stock price today?

One share of SPNE stock can currently be purchased for approximately $11.95.

How much money does SeaSpine make?

SeaSpine has a market capitalization of $435.48 million and generates $154.35 million in revenue each year. The medical equipment provider earns $-43.18 million in net income (profit) each year or ($1.47) on an earnings per share basis.

How many employees does SeaSpine have?

SeaSpine employs 421 workers across the globe.

What is SeaSpine's official website?

The official website for SeaSpine is www.seaspine.com.

Where are SeaSpine's headquarters?

SeaSpine is headquartered at 5770 ARMADA DRIVE, CARLSBAD CA, 92008.

How can I contact SeaSpine?

SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at (760) 727-8399 or via email at [email protected].

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.